562
Views
24
CrossRef citations to date
0
Altmetric
Review

Calpain-2 as a therapeutic target for acute neuronal injury

, &
Pages 19-29 | Received 20 Jun 2017, Accepted 22 Nov 2017, Published online: 28 Nov 2017
 

ABSTRACT

Introduction: Calpains represent a family of neutral, calcium-dependent proteases, which modify the function of their target proteins by partial truncation. These proteases have been implicated in numerous cell functions, including cell division, proliferation, migration, and death. In the CNS, where calpain-1 and calpain-2 are the main calpain isoforms, their activation has been linked to synaptic plasticity as well as to neurodegeneration. This review will focus on the role of calpain-2 in acute neuronal injury and discuss the possibility of developing selective calpain-2 inhibitors for therapeutic purposes.

Areas covered: This review covers the literature showing how calpain-2 is implicated in neuronal death in a number of pathological conditions. The possibility of developing new selective calpain-2 inhibitors for treating these conditions is discussed.

Expert opinion: As evidence accumulates that calpain-2 activation participates in acute neuronal injury, there is interest in developing therapeutic approaches using selective calpain-2 inhibitors. Recent data indicate the potential use of such inhibitors in various pathologies associated with acute neuronal death. The possibility of extending the use of such inhibitors to more chronic forms of neurodegeneration is discussed.

Article Highlights

  • Calpain-2 is neurodegenerative and several downstream signaling pathways lead to neuronal death.

  • Calpain-2 activation is delayed and prolonged in two models of acute neuronal injury, acute glaucoma, and TBI.

  • In TBI, the extent of cell death is directly related to calpain-2 activation.

  • A selective calpain-2 inhibitor provides a highly significant degree of neuroprotection when administered after the injury in both acute glaucoma and TBI.

  • A selective calpain-2 inhibitor could be a potential candidate for the treatment of several neurological disorders associated with acute neuronal death.

This box summarizes key points contained in the article.

Declaration of interest

Y. Wang, X. Bi and M. Baudry are co-founders of NeurAegis, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This work was supported by grants P01NS045260-01 from NINDS (PI: Dr. C.M. Gall), and grant R21NS057128 from NINDS to M. Baudry, and grant R15MH101703 from NIMH to X. Bi. X. Bi is also supported by funds from the Daljit and Elaine Sarkaria Chair.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.